Major advances in science and technology, including target-based drug discovery methods and machine learning tools, have rapidly increased the rate of development of breakthrough therapies in the biologics industry. To begin delivering the impacts of their new drugs to the patient population, biopharma companies need their supply chains and manufacturing facilities to keep up with the increasing demand.
With so many newly developed products to accommodate, biopharma manufacturing facilities need to plan long-term for the changes coming through the development pipeline. They may need to address resource allocation, make tradeoff decisions, and rearrange schedules to accommodate capacity changes.
To achieve accurate long-range planning capabilities, some biopharma manufacturers have started utilizing a factory digital twin. The digital twin creates a virtual replica of the manufacturing site and uses an algorithm to test potential changes and specific scenarios to predict resulting outcomes. These capabilities help biopharma companies identify the adjustments needed to account for additional products or organizational changes in the future. According to McKinsey, using a digital twin for long-range production planning and predicting future outcomes results in a 5% increase in revenue on average.
Biopharma companies have been using VirtECS, our digital twin software, to create a virtual model of their manufacturing site and proactively adapt to future production changes. VirtECS’ sophisticated math-based algorithm can quickly analyze potential scenarios to generate insights that help them better prepare for demand planning, supply planning, and long-term capacity utilization in their facilities. Keep reading while we dive into the benefits a digital twin can provide in each area of planning.
Demand & Supply Planning Benefits
There are a wide range of factors that contribute to a biopharma production facility’s desired output, but one of the most important elements is the demand forecast. Biopharma companies look closely at historical data, population studies, market changes, industry regulations, and other sources to gauge the predicted demand for a product in the months or years ahead.
When pairing demand forecasts with a digital twin, manufacturing facilities can plan when they will scale production up or down in response to the market projections. VirtECS clients have been able to strengthen the results of their demand planning efforts by making strategic adjustments to their production plan and ensuring they can maximize their output of high-demand drugs or minimize waste when demand dips. The optimized output has had significant financial rewards. “Our capacity planning tool helped our client maximize their profits by making as much product as possible to meet forecasts,” said Steve Harding, President of APCI.
While designing production plans based on demand forecasts, biopharma companies can also use a digital twin to coordinate subsequent supply plans. With desired product output determined, the digital twin can optimize the allocation of resources to accommodate the highest-priority deadlines and ensure there is a sufficient amount of each. If there are projected disruptions to the supply chain or changes in material availability, the digital twin can also recalculate plans to avoid wasting valuable production time.
Capacity Utilization Benefits
As new products reach the final stages of development and approval, biopharma companies need to allocate production capacity for the additional demand at their manufacturing sites. The virtual plant model created with digital twin software can analyze the available capacity at multiple sites, making it easier to find the ideal location for new products. The digital twin can then create plans that optimize capacity utilization and fit deadlines into the schedule with fewer disruptions or changes.
Software like VirtECS has the ability to balance the site’s current deadlines alongside future priorities to optimize the production schedule and ensure there will be adequate capacity when new products are approved. When Sanofi realized they would need to accommodate production of a new biologics product at an existing manufacturing site, they turned to VirtECS. Using the model, they made strategic long-term plans to shift production and integrate the new product without disrupting the plant’s other priorities. “What demonstrated the real power of VirtECS was that it gave schedulers an interface to manage,” said Jon Forstrom, Director of Manufacturing Science and Technology at Sanofi. “Their planning horizon went from being just a few weeks to more than three years.”
Using a digital twin to analyze available capacity has also helped biopharma manufacturers make informed, data-based investment decisions to guide the facility in the ideal direction. They can analyze the outcomes of differing plans to evaluate where their investment will result in the greatest increases in capacity and overall returns. To learn more about VirtECS’ capacity planning capabilities and Sanofi’s experience utilizing the tool to improve their capacity utilization, check out our recent case study.
